NaturegenicCompanyOverview
Company
CRISPR/Cas-based genome editing
image
Using our proprietary tool box of CRISPR/Cas genome editing enztmes, we develop novel traits in tomato, lettuce, sotbeanm and corn.
image
We develop the DNA-free genome editing technology for human nutrition and health.
Naturegenic Competitiveness

Development of Innovative NEW Drugs Based on CRISPR Genome Editing Technology

  • secure original technology

    CRISPR PLUS™

    New gfCas12a

    Glyco-engineering

  • Platform Development

    CRISPR anti-cancer drug platform (Cancerase™)

    Plant-derived biopharmaceutical platform (PDB)

  • Innovative new drug for next generation

    CRISPR new drug

    Plant-derived protein treatment

Commercialization Strategy
image
Breeding with CRISPR Non-GMO technology to improve traits without introducing foreign genes and Smart farming
(*)ADCC: Antibody-dependent cellular cytotoxicity (ADCC) is a mechanism of cell-mediated immune defense whereby an effector cell of the immune system actively lyses a target cell, whose membrane-surface antigens have been bound by specific antibodies.